ACTINIUM PHARMACEUTICALS INC (ATNM) Forecast, Price Target & Analyst Ratings

NYSEARCA:ATNM • US00507W2061

Current stock price

0.99 USD
-0.04 (-3.88%)
At close:
0.98 USD
-0.01 (-1.01%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ACTINIUM PHARMACEUTICALS INC (ATNM).

Forecast Snapshot

Consensus Price Target

Price Target
$5.10
+ 415.15% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 7, 2026
Period
Q4 / 2025
EPS Estimate
-$0.19
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
81.82%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$5.10
Upside
+ 415.15%
From current price of $0.99 to mean target of $5.10, Based on 11 analyst forecasts
Low
$2.02
Median
$5.10
High
$9.45

Price Target Revisions

1 Month
0.00%
3 Months
0.00%

Price Target Summary

11 Wall Street analysts provided a forecast for the next 12 months for ATNM. The average price target is 5.1 USD. This implies a price increase of 415.15% is expected in the next year compared to the current price of 0.99.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

ATNM Current Analyst RatingATNM Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4 5

Analyst Ratings History

ATNM Historical Analyst RatingsATNM Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
81.82%
ATNM was analyzed by 11 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about ATNM.
In the previous month the buy percentage consensus was at a similar level.
ATNM was analyzed by 11 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2025-06-24HC Wainwright & Co.Reiterate Buy -> Buy
2025-05-12HC Wainwright & Co.Reiterate Buy -> Buy
2025-04-28HC Wainwright & Co.Reiterate Buy -> Buy
2025-04-01HC Wainwright & Co.Reiterate Buy -> Buy
2025-03-27HC Wainwright & Co.Reiterate Buy -> Buy
2025-03-25HC Wainwright & Co.Reiterate Buy -> Buy
2025-03-20HC Wainwright & Co.Reiterate Buy -> Buy
2025-03-18HC Wainwright & Co.Reiterate Buy -> Buy
2025-03-11HC Wainwright & Co.Reiterate Buy -> Buy
2024-11-19Stephens & Co.Reiterate Overweight -> Overweight
2024-11-15HC Wainwright & Co.Reiterate Buy -> Buy
2024-08-06Maxim GroupMaintains Buy -> Buy
2024-08-06HC Wainwright & Co.Maintains Buy -> Buy
2024-07-26HC Wainwright & Co.Reiterate Buy -> Buy
2024-06-17HC Wainwright & Co.Reiterate Buy -> Buy
2024-05-21HC Wainwright & Co.Reiterate Buy -> Buy
2024-05-14Stephens & Co.Initiate Overweight
2024-05-02HC Wainwright & Co.Reiterate Buy -> Buy
2024-04-30Cantor FitzgeraldReiterate Overweight -> Overweight
2024-04-29HC Wainwright & Co.Reiterate Buy -> Buy
2024-04-01Cantor FitzgeraldReiterate Overweight -> Overweight
2024-04-01HC Wainwright & Co.Reiterate Buy -> Buy
2024-03-26HC Wainwright & Co.Reiterate Buy -> Buy
2024-03-19Maxim GroupMaintains Buy -> Buy
2024-03-19HC Wainwright & Co.Maintains Buy -> Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 7, 2026
Period
Q4 / 2025
EPS Estimate
-$0.19
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
9.33%
Number of Analysts
6

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%

Next Earnings Summary

ATNM is expected to report earnings on 5/7/2026. The consensus EPS estimate for the next earnings is -0.19 USD and the consensus revenue estimate is 0 USD.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2025 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
ATNM revenue by date.ATNM revenue by date.
1.144M1.03M
-9.97%		81K
-92.14%		193.117K
-100.00%		91.8K
-100.00%		43.55M43.678M
0.29%		125.24M
186.73%		209.25M
67.08%		301.73M
44.20%		392.37M
30.04%		550.42M
40.28%
EBITDA
YoY % growth
ATNM ebitda by date.ATNM ebitda by date.
-24.44M
-11.36%		-33.405M
-36.68%		-51.13M
-53.06%		-49.572M
18.01%		-37.332M
10.95%		-39.474M
-5.74%		-45.084M
-14.21%		-50.49M
-11.99%		N/AN/AN/AN/AN/A
EBIT
YoY % growth
ATNM ebit by date.ATNM ebit by date.
-24.964M
-11.48%		-34.104M
-36.61%		-51.92M
-52.24%		-47.784M
18.87%		-36.85M
12.52%		-36.496M
0.96%		-17.213M
52.84%		-22.123M
-28.53%		28.143M
227.21%		75.484M
168.22%		132.52M
75.56%		184.68M
39.36%		242.67M
31.40%
Operating Margin
ATNM operating margin by date.ATNM operating margin by date.
-2,182.17%-3,311.07%-64,098.77%-24,743.57%-40,141.11%N/A-39.52%-50.65%22.47%36.07%43.92%47.07%44.09%
EPS
YoY % growth
ATNM eps by date.ATNM eps by date.
-1.20
41.18%		-1.37
-14.17%		-1.84
-34.31%		-1.43
30.98%		-1.10
13.26%		-0.76
31.17%		-0.68
10.31%		-0.62
8.50%		-0.18
70.49%		0.12
163.89%		0.73
521.74%		1.15
57.34%		0.77
-33.33%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q4 / 25 Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth		-0.19
9.33%		-0.20
60.00%		-0.21
2.64%		-0.14
10.75%		-0.11
41.07%
Revenue
Q2Q % growth
-100.00%
EBITDA
Q2Q % growth		-6.834M
6.49%		N/AN/AN/AN/A
EBIT
Q2Q % growth		-7.349M
2.08%		-7.87M
52.70%		-8.294M
-10.54%		-9.114M
9.79%		-9.73M
-32.39%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

ATNM Yearly Revenue VS EstimatesATNM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
ATNM Yearly EPS VS EstimatesATNM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -5 -10 -15

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
13.56%
EPS Next 5 Year
13.16%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
508.68%
Revenue Next 5 Year
265.08%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
1.85%
EBIT Next 5 Year
-1.39%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

ACTINIUM PHARMACEUTICALS INC / ATNM Forecast FAQ

Can you provide the average price target for ACTINIUM PHARMACEUTICALS INC stock?

11 analysts have analysed ATNM and the average price target is 5.1 USD. This implies a price increase of 415.15% is expected in the next year compared to the current price of 0.99.

Can you provide the upcoming earnings date for ACTINIUM PHARMACEUTICALS INC?

ACTINIUM PHARMACEUTICALS INC (ATNM) will report earnings on 2026-05-07.

Can you provide the consensus estimates for ACTINIUM PHARMACEUTICALS INC next earnings?

The consensus EPS estimate for the next earnings of ACTINIUM PHARMACEUTICALS INC (ATNM) is -0.19 USD and the consensus revenue estimate is 0 USD.

Can you provide the expected long term growth rate for ACTINIUM PHARMACEUTICALS INC stock?

The expected long term growth rate for ACTINIUM PHARMACEUTICALS INC (ATNM) is 508.68%.